Abstract: Antibodies that protect against respiratory viral infections including human parainfluenza viruses (HPIV), respiratory syncytial virus (RSV), and human metapneumovirus (HMPV) are described. Certain antibodies disclosed herein neutralize more than one virus (e.g., RSV and HMPV). The binding fragments of the antibodies can be engineered into numerous formats including those that provide simultaneous protection against multiple viruses.

Abstract: A suspension assembly for a camera lens element includes a support member with a wire attach structure and a moving member coupled to the support member. The moving member includes a plate, flexure arms extending from the plate and coupled to the support member, and a wire attach structure. A bearing supports the plate of the moving member for movement with respect to the support member. A shape memory alloy wire is coupled to and extends between the wire attach structures of the support member and the moving member. The limiter limits a range of movement of the moving member with respect to the support member, and in embodiments includes an opening in one of the moving member plate and the support member, and a stop that includes an engagement portion extending into the opening in the other of the moving member plate and the support member.

Abstract: A fluidic connector (10) includes a female tubular fitting (14), a male tubular fitting (12), and a generally U-shaped metal pin (16) mounted astride the female fitting (14). The pin (16) is axially movable on the female fitting (14) from an inoperative position in which branches (16a, 16b) of the pin are held spaced apart by the female fitting (14), to an operative position in which portions (31) of the branches are located at the level of at least one slit (32) of the female fitting (14) and are able to pass through the slit by elastic return. The male fitting (12) includes a part (12a2) configured to be engaged in the female fitting (14) and to cooperate directly with the branches (16a, 16b) of the pin (16) move the male fitting from its inoperative position to its operative position.

Abstract: The present disclosure provides compositions and methods for improved pre-targeted radioimmunotherapeutics (PRIT) to treat various hematological disorders, such as B cell hyperproliferative disorders and solid tumors. The disclosed compositions include bispecific antibody compositions having a first domain that specifically bind to an antigen such as CD38, BCMA, Muc1, GPRC5D, or Slam7, and a second domain that specifically binds to a radioactive ligand. Methods include administering the disclosed bispecific antibody reagent and separately administering the radioactive ligand. In some embodiments, a clearing agent is also administered. In some embodiments, the therapeutic methods comprise administering a combination of two or more bispecific antibody reagents. In some embodiments, an enhancing agent, such as ATRA, gamma secretase inhibitor, or dextramethasone, is also administered to enhance expression of the target antigen on the target cells.

Abstract: Antibodies that bind the tumor (T) antigen of the Merkel cell polyomavirus are disclosed. The antibodies can be use used in cell-based immunotherapies, antibody-based therapies, diagnostics, and detection assays, among other uses.

Abstract: A method of forming a self-sealing fuel tank includes: providing a container including internal surfaces and external surfaces and configured to hold a fuel; forming a latex coating layer over at least a portion of the internal surfaces and/or external surfaces; depositing or encapsulating an environmental layer over at least a portion of the latex coating layer; where the latex coating layer swells when contacted with the fuel; and where the latex coating layer is formed from a latex coating composition that is substantially free of a non-ionic associative thickener.

Abstract: The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.

Abstract: The present disclosure provides improved compositions for the homology directed repair of the human globin locus for the prevention, treatment, or amelioration of at least one symptom of a hemoglobinopathy.

Abstract: Methods of modeling the in vivo efficacy of drug combinations for the treatment or prevention of viral infection are described. The described methods combine data for single drugs and drug combinations from pharmacokinetic, pharmacodynamic, and viral dynamics models under a series of estimated in vivo drug potencies to provide predictions of the in vivo effects of the drug combinations. These predictions can be used to more accurately select drugs and drug treatment regimens that can be successful in controlling viral infection in animal studies, clinical trials and in medical or veterinary interventions. Also described is a method of treating or preventing filovirus infections using combinations of orally available drugs based on predictions from the modeling methods.

Abstract: Disclosed is a fluid connection device (10) comprising a male connector (12) and a female connector (14), which are configured to be fitted one inside the other along an axis X so as to produce a fluid connection, and at least one annular seal (16) carried by one of the connectors and configured to engage with the other connector in order to ensure a seal between the connectors, the connectors being configured to be fastened to each other by resilient snap-fastening and to retain, after fastening, at least one degree of freedom with respect to each other, characterised in that the connectors are fastened together by a double fastening by resilient snap-fastening and by bayonet, this resilient snap-fastening being configured to be irreversible without deterioration so that, after fastening, the device cannot be dismantled without deterioration.

Abstract: A non-return insert valve (100) for a fluid circuit, in particular of a vehicle, this valve (100) being configured to be inserted into a pipe (12) and comprising: a tubular body (102), a ring (104) comprising guides (140), a piston (106) configured to slidingly cooperate with said guides (140) and carrying a seal (146), and an elastically deformable member (108) for biasing said seal (146) in axial support against a seat (124) of the tubular body (102), said piston (106) comprising at its external periphery lugs (166) which are configured to be supported axially against an internal cylindrical shoulder (126) of said body (102), in order to precisely define a first position of the piston, the fluid being intended to flow between these lugs (166) when the piston (106) is in a second position.

Abstract: Provided are methods, kits and compositions related to toxicity associated with administration of cell therapy for the treatment of diseases or conditions, e.g., cancer, including methods for use in predicting and treating a toxicity. In some embodiments, the toxicity is a neurotoxicity or cytokine release syndrome (CRS), such as a severe neurotoxicity or a severe CRS. The methods generally involve detecting a parameter of a biomarker or individually a parameter of each biomarker in a panel of biomarkers, such as a concentration, amount or activity, and comparing the detected parameter to a reference value for the parameter to determine if the subject is at risk for developing the toxicity, such as neurotoxicity or CRS or severe neurotoxicity or severe CRS.

Abstract: An apparatus is described. The apparatus may include a substrate and one or more sensors mounted to the substrate. The one or more sensors may be mounted to the substrate using adhesive material and one or more spot welds.

Abstract: Single-domain antibodies that bind receptor tyrosine kinase (ROR1) are described. The single-domain antibodies can be used for multiple purposes including in research, imaging, diagnosis, and treatment of ROR1-related conditions. The disclosed single-domain antibodies can be used as anti-cancer therapeutics such as antibody-drug conjugates, multi-domain binding molecules, or recombinant receptors or can be used as cancer imaging/diagnostic agents.

Abstract: Chimeric antigen receptors (CAR) that bind Preferentially Expressed Antigen in Melanoma (PRAME) ALY(SEQ ID NO: 94)/HLA-A2 are disclosed. The CAR can be used to treat PRAME/HLA-A2 expressing cancers such as the t(8;21), Inv(16), and KMT2A-r forms of acute myeloid leukemia (AML).

Abstract: The use of luteinizing hormone receptor (LHR) binding agents and luteinizing hormone (LH) agonists to enrich for primitive hematopoietic stem cell (pHSC) populations, to target pHSC for ablation, and/or to expand pHSC populations are described. The methods can be used to prepare therapeutic hematopoietic stem cell (HSC) populations, to prepare patients for therapeutic HSC transplants, and/or to treat malignancies, such as those associated with hyperproliferative HSC.

Abstract: Anti-Epstein Barr Virus (EBV) vaccines are described herein. The EBV vaccine antigens are linked to a multimerization domain, for example, presented on a circular tandem repeat protein (cTRP) scaffold or linked to a C4b multimerization domain. The vaccines can be used to treat and/or reduce the risk of EBV infection and to treat and/or reduce the risk of complications associated with EBV infection, such as infectious mononucleosis, lymphoproliferative disorders, carcinomas, and smooth muscle tumors.

Abstract: Delta-like non-canonical Notch ligand 1 (DLK1) inhibitors are disclosed. The DLK1 inhibitors can be used to treat cancers such as myelodysplastic syndrome (MDS), and cancers of the liver, breast, brain, pancreas, colon, lung, kidney, ovary, testes, and/or adrenal gland, among other uses described herein.

Abstract: The invention in relates in particular to a rubber composition able to be extruded to form an inner layer of a fuel hose for a motor vehicle, a method for preparing this composition, this hose and a fuel feed circuit of a motor vehicle incorporating it. This composition is based on at least one fluoroelastomer (FKM) and includes a filler and a micronised powder of at least one fluorinated thermoplastic polymer which are dispersed in said at least one fluoroelastomer. According to the invention, the composition includes said micronised powder according to a quantity greater than 20 phr (phr: parts by weight per 100 parts of elastomer(s)), and the filler includes at least one inorganic filler having lamellas which has an aspect ratio greater than 30 and which is based on a phyllosilicate chosen from kaolinite and micas, or is based on a talc.

Abstract: Etchant solutions, pretreatment and methods for etching electroless nickel on metallic materials are provided herein. More specifically, etchant solutions for selectively removing electroless nickel from the surface of metallic materials containing copper, and optionally as containing stainless steel, methods of etching and pretreatment are provided.